Our GMP, Your IND

Advancing Vaccines and BioTherapeutics

Solutions Through Immunology

Advancing Vaccines and BioTherapeutics

Breakthroughs Delivered

Advancing Vaccines and BioTherapeutics

About ABL

ABL provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market.

Learn More
Spotlight

ABL Europe and SillaJen Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies

SillaJen, Inc., a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL Europe, an ABL, Inc. company providing dedicated viral vector GMP services for gene therapy, oncolytic products and vaccines for all stages of clinical supply, have expanded their strategic manufacturing collaboration.

Read More

Aushon BioSystems and ABL, Inc. Announce Adoption of the Cira™ Platform for Multiplex and Ultrasensitive Biomarker Testing

ABL strengthens biomarker capabilities for a wide range of disease states with the Cira platform.

Read More

ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line

ABL is proud to announce the successful expansion of its aseptic fill/finish operations at its Rockville, MD GMP biomanufacturing facility with the installation of a new, fully automated vial filling system.

Read More

ABL, Inc. Earned GCLP Certificate of Accreditation

In Q1 2017, ABL was awarded a certificate of full accreditation after satisfactorily implementing the requirements set out in the Good Clinical Laboratory Practice (GCLP), an international standard developed by the World Health Organization (WHO) to close the gap between preclinical GLP and GCP testing.

Learn More